We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010
News

Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010

Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010
News

Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmaNet Development Group, Inc., announce that it is hosting a complimentary symposium entitled "Safety and Value: Critical Success Factors for Post-Approval Research" at the Royal College of Surgeons in London, United Kingdom on June 3, 2010.

Post-approval studies are essential in characterizing the real-world performance of medical products in terms of safety, effectiveness, economic value and quality of life.

During this symposium, industry leaders will join PharmaNet experts to discuss techniques to optimize post-approval research including:

• Strategic Post-Approval Research Planning, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet

• The Evolving Post-Approval Regulatory Environment in Europe, Franz Buchholzer, Vice President, Regulatory Operations, PharmaNet

• Issues in Safety, Epidemiology, and Risk Management, Rav Seeruthun, Head of CNS and GI, Eisai Europe and George Seaton, Clinical Trials Manager, Eisai Europe

• Obtaining Real-World Evidence through Observational Research and Patient Registries, Ron Weishaar, Executive Director, Observational Research, PharmaNet

• Establishing Product Value through Health Economics and Outcomes Research (HEOR), Michael Nelson, Executive Director, Health Economics and Outcomes Research, PharmaNet

• Post-Approval Case Studies, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet.
Advertisement